C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks [Abstract 74] | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks [Abstract 74]

Foster GR, Agarwal K, Cramp M, Moreea S, Barclay ST, Collier J, et al. C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks [Abstract 74]. In The Liver Meeting. 2016.

Publication Type:

Conference Paper

Authors:

Graham R. Foster; Kosh Agarwal; Matthew Cramp; Sulleman Moreea; Stephen T. Barclay; Jane Collier; Ashley S. Brown; Stephen D. Ryder; Andrew Ustianowski; Daniel M. Forton; Ray Fox; Fiona Gordon; William M. Rosenberg; David J. Mutimer; Jiejun Du; Christopher L. Gilbert; Janice Wahl; Eliav Barr; Barbara Haber

Source:

The Liver Meeting, Number 74 (2016)

Abstract:

74

Cited On:

Peginterferon/Ribavirin-Experienced, Genotype 3 Patients With Compensated Cirrhosis

Export Citation:

RIS Format

Top